Adult Stem Cell Patient Treatments Progress in U.S. Phase II Cardiac and Vascular Regeneration Clinical Trials; Patient Enrollment On Track With Guidance

Conference Call May 15, 2014 at 4:30 PM Eastern Time

Focus on Cardiovascular Regeneration Sets Foundation for Continued Clinical Progress

ANN ARBOR, Mich., Nov. 7, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today reported financial results for the first fiscal quarter ended September 30, 2008. The Company also reported several recent clinical and operational

Conference Call Today at 4:30 PM Eastern Time

Conference Call Today at 4:30 PM Eastern Time

Conference Call Today at 4:30 PM ET

ANN ARBOR, Mich., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today reported that the company has regained compliance with the $1.00

ANN ARBOR, Mich., Nov. 15, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that on November 14, 2013, the Company was notified

-- Patent Covers Bone Marrow, Blood and Cord Blood-Sourced Products --